Information Provided By: 
Fly News Breaks for August 7, 2019
AXGN
Aug 7, 2019 | 14:06 EDT
JMP Securities analyst David Turkaly reiterated an Outperform rating on AxoGen, but lowered his price target on the shares to $28 from $43 following the company's Q2 results. The analyst continues to believe that AxoGen's Avance offers a unique, differentiated product that can become a new standard of care in long-gap nerve repair, but acknowledges that new reps in the field may take more time to develop than he previously anticipated given the cadence over the past few quarters.
News For AXGN From the Last 2 Days
There are no results for your query AXGN
